Physician profile
Brian Wayne Toedebusch
NPI 1588929566
$1,177.00
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.12 · 2020: $32.89 · 2021: $696 · 2022: $147 · 2023: $165 · 2024: $37.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $202.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $695.55 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $103.59 | 2022-2023 | Dupixent |
| Sanofi-Aventis U.S. LLC | $41.20 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $35.08 | 2019 | |
| Grifols USA, LLC | $34.92 | 2022-2023 | Prolastin-C Liquid |
| Lifenet Health | $22.49 | 2024 | Theragenesis Wound Matrix |
| Takeda Pharmaceuticals U.S.A., INC. | $21.23 | 2023 | Glassia |
| Abbott Laboratories | $20.24 | 2023 | Freestyle Libre 3 |
| Depuy Synthes Sales INC. | $19.58 | 2020 | |
| Merck Sharp & Dohme LLC | $19.49 | 2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $18.67 | 2023 | Fasenra |
| Harmony Biosciences LLC | $17.58 | 2022 | |
| Zimmer Biomet Holdings, INC. | $17.48 | 2022 | |
| Medtronic, INC. | $15.17 | 2024 | Synchromedii |
| Amgen INC. | $15.15 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.12 | 2022 | |
| Philips North America LLC | $15.00 | 2023 | |
| Intercept Pharmaceuticals, INC. | $13.31 | 2022 | |
| Pacira Therapeutics, INC. | $13.12 | 2019 | |
| Shire North American Group INC | $12.03 | 2019 | |
| Convatec INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Toedebusch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.